-
Tytuł:
-
The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study.
-
Autorzy:
-
Nam JH; Division of Gastroenterology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Jang SI; Department of Preventive Medicine, Institute of Health Services Research, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Park HS; Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Kim JH; Division of Gastroenterology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Lee JK; Division of Gastroenterology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Lim YJ; Division of Gastroenterology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Koh MS; Division of Gastroenterology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Lee JH; Division of Gastroenterology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Park S; Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea.
Nam CM; Department of Preventive Medicine, Institute of Health Services Research, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Park EC; Department of Preventive Medicine, Institute of Health Services Research, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. .
-
Źródło:
-
BMC gastroenterology [BMC Gastroenterol] 2021 Nov 23; Vol. 21 (1), pp. 440. Date of Electronic Publication: 2021 Nov 23.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: London : BioMed Central, [2001-
-
MeSH Terms:
-
Hormone Replacement Therapy*
Stomach Neoplasms*
Cohort Studies ; Humans ; Menopause ; Republic of Korea/epidemiology
-
References:
-
Nat Rev Endocrinol. 2017 Apr;13(4):220-231. (PMID: 27716751)
United European Gastroenterol J. 2017 Dec;5(8):1123-1128. (PMID: 29238591)
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1688-94. (PMID: 19505900)
Int J Colorectal Dis. 2013 Jun;28(6):737-49. (PMID: 23319136)
Cancer. 2015 Sep 15;121(18):3261-71. (PMID: 26036212)
Maturitas. 2014 Nov;79(3):287-91. (PMID: 25156453)
Int J Cancer. 2017 Apr 1;140(7):1693-1699. (PMID: 28006838)
Cancer Causes Control. 2018 Jun;29(6):495-505. (PMID: 29671181)
Cancer Res Treat. 2018 Apr;50(2):303-316. (PMID: 29566481)
J Clin Oncol. 2012 Nov 10;30(32):3983-90. (PMID: 23008295)
Cancer. 2020 Mar 1;126(5):1041-1050. (PMID: 31873947)
Pathol Oncol Res. 2020 Jan;26(1):63-78. (PMID: 30617760)
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2609-18. (PMID: 18829444)
Eur J Cancer. 2016 Jan;52:138-54. (PMID: 26687833)
N Engl J Med. 2004 Mar 4;350(10):991-1004. (PMID: 14999111)
Lancet. 2003 Aug 9;362(9382):419-27. (PMID: 12927427)
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2835-41. (PMID: 19843681)
Clin Cancer Res. 2013 Nov 1;19(21):5842-8. (PMID: 23965904)
BMC Cancer. 2014 May 25;14:371. (PMID: 24885829)
Stat Med. 2014 Mar 15;33(6):1057-69. (PMID: 24123228)
Eur J Cancer. 2017 Sep;83:279-289. (PMID: 28763692)
Breast Cancer Res Treat. 2014 Jun;145(2):535-43. (PMID: 24781971)
Int J Cancer. 2018 May 15;142(10):2003-2010. (PMID: 29270993)
Eur J Cancer. 2017 Oct;84:60-68. (PMID: 28783542)
Int J Cancer. 2012 May 15;130(10):2387-96. (PMID: 21671473)
BMJ Open. 2017 Nov 15;7(11):e017639. (PMID: 29146641)
BMC Cancer. 2019 Dec 9;19(1):1199. (PMID: 31818262)
Lancet Oncol. 2008 Apr;9(4):385-91. (PMID: 18374292)
PLoS One. 2016 Oct 24;11(10):e0164620. (PMID: 27776142)
Med Care. 2016 Feb;54(2):188-94. (PMID: 26683778)
Am J Epidemiol. 2010 Feb 15;171(4):415-25. (PMID: 20067917)
Clin Colorectal Cancer. 2018 Jun;17(2):e281-e288. (PMID: 29398422)
Stat Biosci. 2017;9(2):489-503. (PMID: 29225713)
N Engl J Med. 2008 Aug 14;359(7):697-708. (PMID: 18703472)
Cancer Res. 2009 Dec 1;69(23):9118-24. (PMID: 19903848)
Int J Cancer. 2020 Aug 15;147(4):1018-1026. (PMID: 31943160)
BMJ. 2012 Oct 09;345:e6409. (PMID: 23048011)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Eur J Epidemiol. 2016 May;31(5):481-9. (PMID: 26758900)
-
Contributed Indexing:
-
Keywords: Cohort study; Dose–response relationship; Gastrointestinal cancer; Menopausal hormone therapy; Mortality
-
Entry Date(s):
-
Date Created: 20211124 Date Completed: 20211125 Latest Revision: 20211127
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8609757
-
DOI:
-
10.1186/s12876-021-02021-y
-
PMID:
-
34814853
-
Background: The effect of menopausal hormone therapy (MHT) on gastrointestinal (GI) cancers is controversial, and no research has been conducted in the East. This study investigates the association between MHT and GI cancer risks in South Korea.
Methods: A prescription-based cohort study was conducted using the NHIS Sample Cohort (2002-2013) of Korea. We used 1:5 propensity score matching, and 22,577 MHT users and 111,113 non-users were selected. Kaplan-Meier survival curves with log-rank tests were used. Cox proportional hazard models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Landmark analysis was used to determine dose-response relationship.
Results: The median follow-up was 79.6 of months. Kaplan-Meier survival curve showed less frequent GI cancer diagnoses in MHT users compared to non-users (0.13 vs. 0.16 per 100,000 person-years). Menopausal hormone therapy was associated with decreased incidence of GI cancer (HR = 0.809, 95%CI = 0.691-0.946) and colorectal cancer (CRC) (HR = 0.757, 95%CI = 0.577-0.995). Gastric cancer (GC) incidence showed marginal significance (HR = 0.787, 95%CI = 0.605-1.023). The mortality from GI cancer was lower in MHT users than in non-users (HR = 0.737, 95%CI = 0.547-0.993). The relationship between MHT and GI cancer was stronger with increasing MHT dose in terms of both incidence (P trend = 0.0002) and mortality (P trend = 0.0064).
Conclusions: The association between MHT use and reduced risks of GI cancers was attributed to CRC and GC and showed a dose-response relationship in a population-based cohort study.
(© 2021. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
